Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics : JMP Securities Adjusts Allogene Therapeutics' Price Target to $27 from $53, Keeps Market Outperform Rating

10/12/2021 | 10:55am EST


ę MT Newswires 2021
All news about ALLOGENE THERAPEUTICS, INC.
08:31aAllogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere..
GL
01/18Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
AQ
01/14INSIDER BUY : Allogene Therapeutics
MT
01/12Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11ALLOGENE THERAPEUTICS : JPM Presentation 2022
PU
01/11Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences
MT
01/11Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
AQ
01/11Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
AQ
01/11US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 38,4 M - -
Net income 2021 -265 M - -
Net cash 2021 492 M - -
P/E ratio 2021 -5,71x
Yield 2021 -
Capitalization 1 599 M 1 599 M -
EV / Sales 2021 28,8x
EV / Sales 2022 436x
Nbr of Employees 301
Free-Float -
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 11,22 $
Average target price 32,38 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-23.86%1 619
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-12.11%50 700
BIONTECH SE-39.30%37 796